Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions.
Biomedical preventions for HIV, such as vaccines, microbicides or pre-exposure prophylaxis (PrEP) with antiretroviral drugs, can each only partially prevent HIV-1 infection in most human trials. Oral PrEP is now FDA approved for HIV-prevention in high risk groups, but partial adherence reduces efficacy. If combined as biomedical preventions (CBP) an HIV vaccine could provide protection when PrEP adherence is low and PrEP could prevent vaccine breakthroughs. Other types of PrEP or microbicides may also be partially protective. When licensed, first generation HIV vaccines are likely to be partially effective. Individuals at risk for HIV may receive an HIV vaccine combined with other biomedical preventions, in series or in parallel, in clinical trials or as part of standard of care, with the goal of maximally increasing HIV prevention. In human studies, it is challenging to determine which preventions are best combined, how they interact and how effective they are. Animal models can determine CBP efficacy, whether additive or synergistic, the efficacy of different products and combinations, dose, timing and mechanisms. CBP studies in macaques have shown that partially or minimally effective candidate HIV vaccines combined with partially effective oral PrEP, vaginal PrEP or microbicide generally provided greater protection than either prevention alone against SIV or SHIV challenges. Since human CBP trials will be complex, animal models can guide their design, sample size, endpoints, correlates and surrogates of protection. This review focuses on animal studies and human models of CBP and discusses implications for HIV prevention.
a Division of HIV/AIDS, Laboratory Branch , Centers for Disease Control and Prevention , Atlanta , GA , USA.
Janet M
JM
McNicholl
D016915:AIDS Vaccines / Q000008:administration & dosage*; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy / Q000379:methods*; D004195:Disease Models, Animal; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D065129:Pre-Exposure Prophylaxis / Q000379:methods*
D016915:AIDS Vaccines; D000890:Anti-Infective Agents
HIV prevention; HIV vaccine; PrEP; clinical trials; macaque
J Infect Dis. 2006 Dec 15;194(12):1661-71
17109337
Lancet. 2016 Jan 2;387(10013):53-60
26364263
N Engl J Med. 2013 Nov 28;369(22):2083-92
24099601
AIDS Res Hum Retroviruses. 2011 Jun;27(6):669-80
21043994
N Engl J Med. 2012 Aug 2;367(5):423-34
22784038
N Engl J Med. 2012 Aug 2;367(5):399-410
22784037
Science. 2010 Sep 3;329(5996):1168-74
20643915
N Engl J Med. 2012 Aug 2;367(5):411-22
22784040
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1513-23
23597282
Proc Natl Acad Sci U S A. 2012 May 29;109(22):8694-8
22586094
Sci Transl Med. 2010 Jan 13;2(14):14ra4
20371467
Lancet. 2013 Jun 15;381(9883):2060-2
23769217
J Infect Dis. 2005 Mar 1;191(5):654-65
15688278
Lancet. 2013 Jun 15;381(9883):2083-90
23769234
PLoS One. 2016 Jan 05;11(1):e0146387
26731116
Sci Transl Med. 2015 Oct 21;7(310):310rv7
26491081
AIDS. 2011 Sep 24;25(15):1833-41
21750420
Am J Prev Med. 2015 Dec;49(6 Suppl 4):S307-18
26590431
PLoS Biol. 2016 Mar 02;14(3):e1002372
26933962
Curr Opin Virol. 2016 Apr;17:57-65
26827165
N Engl J Med. 2015 Feb 5;372(6):509-18
25651245
Cell. 2014 Nov 20;159(5):969-72
25416935
J Infect Dis. 2011 Apr 1;203(7):969-75
21402548
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):265-75
21471820
N Engl J Med. 2010 Dec 30;363(27):2587-99
21091279
N Engl J Med. 2015 Dec 3;373(23):2237-46
26624850
AIDS Res Hum Retroviruses. 2012 Sep;28(9):1063-72
22214267
Am J Reprod Immunol. 2013 Feb;69 Suppl 1:95-105
23279040
N Engl J Med. 2016 Dec;375(22):2121-2132
26900902
J Virol. 2011 Jul;85(13):6610-7
21525346
Lancet Infect Dis. 2011 Jul;11(7):507-15
21570355
Curr Opin HIV AIDS. 2013 Jul;8(4):295-303
23698560
AIDS Res Hum Retroviruses. 2014 Nov;30(11):1072-81
24914761
Biologicals. 2016 Mar;44(2):73-89
26776940
N Engl J Med. 2012 Apr 5;366(14):1275-86
22475592
Annu Rev Med. 2015;66:423-37
25341006
N Engl J Med. 2009 Dec 3;361(23):2209-20
19843557
Lancet. 2008 Nov 29;372(9653):1881-93
19012954
Biologicals. 2016 Mar;44(2):90-110
26732973
J Virol. 2013 Feb;87(3):1708-19
23175374